ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease
VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ('ME Therapeutics' or the 'Company') (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support the research and development of ME Therapeutic's mRNA therapeutic program targeting myeloid cell biology for the treatment of cancer and inflammatory disease.
'We are pleased to receive this support from NRC IRAP, which builds on advisory services and funding received in past years, to allow us to further advance preclinical studies for our mRNA therapeutic candidates that target key myeloid cell pathways,' said Salim Dhanji, CEO of ME Therapeutics. 'Our team at ME Therapeutics passionately believes myeloid cell-derived mRNA therapies represent the next wave of treatments for patients with cancer and inflammatory disease who today have limited treatment options, and we are committed to bringing these potential new approaches to the clinic as soon as possible.'
ME Therapeutics's proprietary mRNA sequences have been engineered to encode for proteins that can modify the immune response in vivo in a targeted manner. Their lead mRNA therapeutic candidate is specifically designed to modulate immune cells in the tumour microenvironment and stimulate an anti-cancer immune response. Preclinical testing has already demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. In addition, ME Therapeutics is exploring design modifications of its mRNA candidates to modulate mRNA expression in a tissue-specific manner for increased efficacy and safety.
About ME Therapeutics
Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Our focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells to enhance anti-cancer immunity. For more information, visit metherapeutics.com.
Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements in this news release include, but are not limited to, statements regarding the Company's collaborations, research plans, the timing for completion of studies and the receipt of results, the intended outcomes of the research, the intended benefits and applications of the Company's technology, and the Company's plans for development of its business. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company, that the results of the testing are not favorable, that future research does not support continued development, that regulatory approvals are not obtained or maintained, that challenges related to mRNA technology development, including delivery, stability, or efficacy issues cannot be overcome, that the Company relies on third-party collaborators and vendors for certain aspects of the research, that the research will not be completed within the expected timeline, that the Company is unable to obtain intellectual property protection for the results, that the Company may require additional funding to advance its research and develop its business, and that the Company's business may not develop as set out in this news release. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ from forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apple Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP Apple class action lawsuit. Captioned Tucker v. Apple Inc., No. 25-cv-05197 (N.D. Cal.), the Apple class action lawsuit charges Apple and certain of Apple's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Apple class action lawsuit, please provide your information here: CASE ALLEGATIONS: The Apple class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Apple misstated the time it would take to integrate the advanced artificial intelligence ('AI')-based Siri features into its devices; (ii) accordingly, it was highly unlikely that these features would be available for the iPhone 16; (iii) the lack of such advanced AI-based features would hurt iPhone 16 sales; and (iv) as a result, Apple's business and/or financial prospects were overstated. The Apple class action lawsuit further alleges that on March 7, 2025, Apple announced it was indefinitely delaying promised updates to its Siri digital assistant. The Apple class action lawsuit alleges that on this news, the price of Apple stock fell. Then, on March 12, 2025, the Apple class action lawsuit further alleges that Morgan Stanley published a report in which analyst Erik Woodring lowered his price target on Apple from $275 to $252, asserting that the delay in introducing advanced Siri features would impact iPhone upgrade cycles throughout 2025 and 2026, and presenting evidence that roughly 50% of iPhone owners who did not upgrade to the iPhone 16 attributed their decision to such delays. On this news, the price of Apple stock fell further, according to the complaint. Thereafter, the Apple class action lawsuit alleges that on April 3, 2025, the Wall Street Journal published an article titled 'Apple and Amazon Promised Us Revolutionary AI. We're Still Waiting,' which stated, in relevant part, that '[w]ith 'more personal' Siri . . . , the tech giant[] marketed features [it] ha[s] yet to deliver,' and suggested that while 'this is challenging technology and the cost of getting it wrong is devastatingly high, especially for [a] compan[y] like Apple . . . that must build trust with customers,' 'the same responsibility applies to marketing: They shouldn't announce products until they're sure they can deliver them.' On this news, the price of Apple stock fell more than 7%, according to the complaint. Finally, on June 9, 2025, Apple hosted its Worldwide Developer Conference ('WWDC'), almost one year to the day after first announcing the suite of supposedly forthcoming Apple Intelligence features at the 2024 WWDC, and Apple failed to announce any new updates regarding advanced Siri features, according to the complaint. On this news, the price of Apple stock fell further, according to the complaint. Last year, Robbins Geller secured a $490 million recovery in a securities fraud class action case alleging Apple CEO Timothy Cook made false and misleading statements to investors – the third-largest securities class action recovery ever in the Northern District of California and the fifth-largest such recovery ever in the Ninth Circuit. In the order granting final approval of the settlement, the court recognized the 'skill and strategic vision, as well as the risk taken by [Robbins Geller]' in securing the sizeable recovery while efficiently managing the 'uniquely complex' aspects of the case against 'highly sophisticated and experienced counsel and defendants.' Learn more by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Apple securities during the Class Period to seek appointment as lead plaintiff in the Apple class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Apple class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Apple class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Apple class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
CNBC
an hour ago
- CNBC
Dollar surge could be short-lived after U.S. strike on Iran
The U.S. dollar surged in early trading on Monday, benefiting from its traditional safe-haven status after U.S. military strikes on Iran — but analysts are warning the gains may be short-lived. The dollar index was up 0.45% at one point, indicating a gain against currencies such as the Japanese yen, the euro and the British pound, as well as the Canadian, Australian and New Zealand dollars. The greenback was last seen trading around 0.4% higher at 9.30 a.m. London time. "The escalation of the Middle East crisis after the US attacks Iran during the weekend is expected to lead to some of the traditional safe haven effects in the market [such] as the oil price is rising, lower equity prices and a stronger dollar," said Kirstine Kundby-Nielsen, fixed income and currency research at Danske Bank. Despite the initial rally, a growing consensus among investment banks suggests the dollar's strength may prove temporary. Some analysts say the Middle East conflict is merely masking concerns over U.S. fiscal policy, trade wars, and weakening international demand for U.S. assets, which are likely to regain focus once the immediate crisis-driven demand fades. The dollar index is down more than 8% this year, reflecting the long-term concern. The U.S. dollar's immediate strength is tied to fears of how Iran might retaliate, with a closure of the Strait of Hormuz — a waterway vital to the transit of oil — at the top of those concerns. Yet, RBC Capital Markets analysts caution that the situation is more complex, noting that Iran has asymmetric capabilities to "strike individual tankers and key ports." "Hence, we do not believe it is a 'full closure or nothing' scenario when it comes to the waterway, and Iran may deploy their asymmetric capabilities to raise the economic cost of the combined US/Israeli operations," said RBC's Halima Croft, a former CIA analyst, in a note to clients. Jordan Rochester, head of FICC strategy for the EMEA region at Mizuho, also expressed some optimism when it came to the possibility of a Strait of Hormuz closure. "It's a bold call but I doubt the strait of Hormuz is blocked and we avoid the $100-130pb oil levels touted by the sell side with Iranian allies such as China likely to be applying pressure to keep oil flows ongoing," he said in a Monday morning note. "The US is also likely to have made energy infrastructure a red line attached to its support of Israel." However, a key indicator of safe-haven demand — the U.S. Treasury market — appears to be telling an entirely different story through its unusually muted reaction. A global crisis typically sends investors flocking to U.S. government debt, but Danske Bank's Kundby-Nielsen said the "impact on US Treasuries is a bit more uncertain given the significant trade deficit and tariffs combined with a potential increase in the supply of Treasuries given the soft fiscal policy". A global trade war is compounding these fiscal concerns. With a July 9 deadline approaching until a reprieve on levies expires, the U.S. is threatening tariffs of up to 50% on most imports from the European Union. "As far as the USD goes, we'd suspect that the USD would be sinking lower if it weren't for the War, largely because the news pertaining to US import tariffs is not particularly good, and because data from outside the US, while weak, does not point to further deterioration relative to the US," said Thierry Wizman and Gareth Berry, Macquarie's currency and rates strategists, in a June 20 note to clients that preceded the U.S. strike on Iran. FX strategists from Bank of America also point out that investors are betting heavily on the decline of the U.S. dollar, which adds momentum to any downward move for the currency. According to the BofA global fund manager survey released on June 16, fund managers currently see short-U.S. dollar as the third most crowded trade — although the survey was carried out before to the United States' involvement in the Middle East conflict.
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Prime Minister Carney in Brussels today for EU-Canada summit
BRUSSELS - Prime Minister Mark Carney is in Belgium today, where he visited a military cemetery before meeting with European Union leaders at an EU-Canada summit. Carney said on social media Sunday that he was in Brussels to launch 'a new era of partnership' between Canada and the European Union for the benefit of workers, businesses and security 'on both sides of the Atlantic.' Carney started the day with a visit to the Antwerp Schoonselhof Military Cemetery where 348 Canadian soldiers are buried. Later, he is expected to meet with Belgian Prime Minister Bart De Wever, European Council President António Costa and European Commission President Ursula von der Leyen. Carney posted on social media early on Monday that he spoke with U.S. President Donald Trump overnight, noting the conversation addressed the need to de-escalate the conflict in the Middle East, their shared commitment of a stronger NATO and progress in ongoing trade talks between Canada and the United States. At the EU-Canada summit, Foreign Affairs Minister Anita Anand and Defence Minister David McGuinty are expected to sign a security and defence agreement with the European bloc in what one European official described last week as one of the most ambitious deals the continent's powers have ever signed with a third country. The security and defence agreement aims to open the door to Canada's participation in the joint purchase of weapons with European countries. It will also lead to Canada's participation in the ReArm Europe initiative, allowing Canada to access a 150-billion-euro program for defence procurement, called Security Action for Europe. Canada will need to sign a second agreement with the European Commission before it can take part in the program. A government official briefing reporters on the trip said the partnership is expected to make procurement easier and more affordable, while also allowing Canada to diversify the sources of equipment. At the EU-Canada summit, leaders are also expected to issue a joint statement to underscore a willingness for continued pressure on Russia to end its war on Ukraine, including through further sanctions, and call for an immediate and permanent ceasefire in Gaza. The joint statement is also expected to touch on climate change, trade and digital and tech policy. Leaders at the EU-Canada summit are also slated to discuss global trade and commit to working towards full ratification and implementation of the Comprehensive Economic and Trade Agreement, the Canada-Europe free trade deal known as CETA. The pact took effect provisionally in 2017, and most of its contents now apply. But all EU countries need to approve CETA before it can take full effect, with 10 members still left to ratify the deal. Carney, Costa and von der Leyen are scheduled to hold a joint press conference in the evening. On Tuesday, Carney travels to The Hague for the NATO summit. The international meetings come as Canada looks to reduce its defence procurement reliance on the United States due to strained relations over tariffs and U.S. President Donald Trump's repeated talk about Canada becoming a U.S. state. This report by The Canadian Press was first published June 23, 2025.
